Fees for Human Drugs

Fees for regulatory activities related to human drugs (pharmaceutical and biological) are currently charged as per the Fees in Respect of Drugs and Medical Devices Regulations [2017-06-30] under the Financial Administration Act. Supporting guidance, forms and current fee links are listed below.

General

Human Drug Submission Evaluation Fees

Before a drug is authorized for sale in Canada, HC reviews it to assess its safety, efficacy and quality. Drug products include prescription and non-prescription pharmaceuticals, biologics, disinfectants and sanitizers with disinfectant claims.

Master File Fees

A Master File is a reference that provides information about specific processes or components used in the manufacturing, processing, or packaging of a drug. The Master File is a useful vehicle for providing information to Health Canada, where that information is confidential business information and is not available to the manufacturer of the dosage form or to the sponsors of a drug submission, DIN (Drug Identification Number) application or clinical trial application (CTA). Health Canada must protect confidential business information in accordance with the law.

Master File fees were last updated May 1, 2017 as per the Notice of Intent published in Canada Gazette on April 22, 2017.

Establishment Licence Fees

Health Canada has facility inspection programs in place to evaluate the compliance of establishments with regulatory requirements to engage in production, importation, testing and distribution of drugs.

Fees for the Right to Sell Drugs

Health Canada monitors human drugs on the Canadian market through post-market surveillance and compliance and enforcement activities. Industry pays an annual fee for the right to maintain and sell human drugs in Canada.

Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: